Drugs for Exfoliation Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 75)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Ketorolac |
Approved |
Phase 4 |
|
74103-06-3, 66635-83-4 |
3826 |
Synonyms:
(.+/-.)-2,3-Dihydro-5-benzoyl-1H-pyrrolizine-1-carboxylic acid
(+-)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylate
(+-)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid
(+-)-isomer
(+-)-Ketorolac
1H-Pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro
5-(phenylcarbonyl)-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid
5-Benzoyl-1,2-dihydro-3H-pyrrolo(1,2a)pyrrole-1-carboxylic acid
5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid
66635-83-4
74103-06-3
AB00053682
AC1L1GSW
AC-545
BRD-A40639672-234-05-7
C07062
CHEBI:105080
CHEMBL469
CID3826
D020910
D08104
DB00465
I14-2832
|
Ketoralac
ketorolac
Ketorolac
Kétorolac
Ketorolac (INN)
Ketorolac [INN:BAN]
Ketorolac tromethamine
Ketorolaco
Ketorolaco [Spanish]
Ketorolacum
Ketorolacum [Latin]
LS-139094
Macril
MolPort-005-933-093
NCGC00185990-01
rac-Ketorolac
RS 37619
RS-37619
SBB067312
STL018674
Toradol
Toradol (TN)
UNII-YZI5105V0L
|
|
2 |
|
Latanoprost |
Approved, Investigational |
Phase 4 |
|
130209-82-4 |
5282380 5311221 |
Synonyms:
130209-82-4
AC1NSK8Q
Ambap130209-82-4
AR-202
Catioprost
CHEBI:6384
CHEMBL1051
CID5311221
CPD000466354
D00356
HMS2051H11
HMS2089J17
isopropyl (5Z,9alpha,11alpha,15R)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinorprost-5-en-1-oate
Isopropyl (5Z,9alpha,11alpha,15R)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinor-prost-5-en-1-oate
isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoate
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoate
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoic acid
Jsp001835
L1167_SIGMA
latanoprost
Latanoprost
Latanoprost (JAN/USAN/INN)
latanoprost free acid
Latanoprostum
MLS000759468
|
MLS001424106
MolPort-003-942-862
Nova-21027
Pfizer brand OF latanoprost
PhXA 41
PhXA34
PhXA34 [as 15(R,S)-isomer]
PhXA41
PHXA41
PHXA-41
propan-2-yl (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoate
Propan-2-yl (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoate
Propan-2-yl (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoic acid
propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate
S1254_Selleck
SAM001246671
SMR000466354
TL8000716
XA41
XA-41
Xalatan
Xalatan (TN)
Xalatan Fixed Flow Device
ZINC12468792
|
|
3 |
|
Bimatoprost |
Approved, Investigational |
Phase 4 |
|
155206-00-1 |
5311027 |
Synonyms:
(5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]cyclopentyl}-N-ethylhept-5-enamide
(Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-5-heptenamide
(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide
155206-00-1
15M
267244-98-4
5-Heptenamide,7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ehtyl-,(5Z)
AC1NSJUW
AGN 192024
AGN-192024
Bimataprost [USAN:INN:BAN]
Bimatoprost
Bimatoprost (JAN/USAN/INN)
Bimatoprost [USAN:INN:BAN]
bimatoprostum
Bimatoprostum
|
CHEBI:39562
CHEBI:51230
CHEMBL1200963
CID5311027
D02724
DB00905
DB06863
I06-1275
I06-1277
Latisse
LS-181817
Lumigan
Lumigan (TN)
NCGC00181745-01
UNII-QXS94885MZ
ZINC04474405
|
|
4 |
|
Timolol |
Approved |
Phase 4 |
|
26839-75-8 |
33624 5478 |
Synonyms:
(-)-3-Morpholino-4-(3-tert-butylamino-2-hydroxypropoxy)-1,2,5-thiadiazole
(2S)-1-((1,1-dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-2-propanol
(2S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol
(2S)-1-[(1,1-dimethylethyl)amino]-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol
(S)-1-(1,1-(Dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-2-propanol
(S)-1-(tert-Butylamino)-3-((4-morpholino-1,2,5-thiadiazol-3-yl)oxy)propan-2-ol
(S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol
(S)-timolol
131628-37-0
194288-09-0
26839-75-8
26921-17-5 (maleate (1:1) salt)
AB00513729
AC1L1PYN
AC1Q59QM
Apo-Timol
Apo-Timop
Aquanil
Betim
Betimol
Betimol (TN)
BIDD:GT0073
Blocadren
BPBio1_001008
BRD-K08806317-050-03-6
BSPBio_000916
C07141
C13H24N4O3S
CAS-26921-17-5
CHEBI:9599
CHEMBL499
CID33624
CPD001456519
D08600
DB00373
DB08625
EINECS 248-032-6
HMS2089I11
HSDB 6533
Istalol
L-714,465
Lopac0_001189
Lopac-T-6394
LS-122231
MK-950
NCGC00016038-01
NCGC00016038-02
|
NCGC00016798-01
NCGC00016798-07
NCGC00022033-02
NCGC00022033-04
NCGC00022033-05
Novo-Timol
Nu-Timolol
Oprea1_640981
Optimol
Phoxal-timolol
Prestwick0_000948
Prestwick1_000948
Prestwick2_000948
Prestwick3_000948
Proflax
S-(-)-3-(3-tert-Butylamino-2-hydroxypropoxy)-4-morpholino-1,2,5-thiadiazole
S(-)-Timolol maleate
SAM002564238
SPBio_003075
ST072193
Temserin
Tenopt
TIM
Timacar
Timacor
Tim-AK
timolol
Timolol
Timolol (INN)
Timolol (TN)
Timolol [USAN]
Timolol anhydrous
Timolol GFS
Timolol maleate
Timolol Maleate, (1:1) Salt
Timololo
Timololum
Timololum [INN-Latin]
Timopic
Timoptic
Timoptic in Ocudose
Timoptic OcuDose
Timoptic-XE
Timoptol
Tocris-0649
UNII-817W3C6175
|
|
5 |
|
Dexamethasone acetate |
Approved, Investigational, Vet_approved |
Phase 4 |
|
1177-87-3 |
|
Synonyms:
16alpha-Methyl-9alpha-fluoroprednisolone 21-acetate
9alpha-Fluoro-16alpha-methylprednisolone acetate
Dexamethasone 21-acetate
|
Dexamethasone acetate anhydrous
Dexamethasone acetate, anhydrous
Dexamethasoni acetas
|
|
6 |
|
Dexamethasone |
Approved, Investigational, Vet_approved |
Phase 4 |
|
50-02-2 |
5743 |
Synonyms:
(3H)-Dexamethasone
.delta.(sup 1)-9-.alpha.-Fluoro-16-.alpha.-methylcortisol
.gamma.corten
137098-19-2
16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol
16.alpha.-Methyl-9.alpha.-fluoroprednisolone
16alpha -Methyl-9alpha -fluoro-1-dehydrocortisol
16alpha -Methyl-9alpha -fluoroprednisolone
16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol
16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol
16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone
16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone
16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone
16alpha-Methyl-9alpha-fluoroprednisolone
16-alpha-Methyl-9-alpha-fluoroprednisolone
16a-Methyl-9a-fluoro-1-dehydrocortisol
16α-Methyl-9α-fluoro-1-dehydrocortisol
16Α-methyl-9α-fluoro-1-dehydrocortisol
1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone
1-Dehydro-16alpha -methyl-9alpha -fluorohydrocortisone
1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone
1-Dehydro-16a-methyl-9a-fluorohydrocortisone
1-Dehydro-16α-methyl-9α-fluorohydrocortisone
23495-06-9
31375_FLUKA
46165_FLUKA
46165_RIEDEL
50-02-2
8054-59-9
9.alpha.-Fluoro-16.alpha.-methylprednisolone
906422-84-2
9a-Fluoro-16a-methylprednisolone
9a-Fluoro-16BETA-methylprednisolone
9A-FLUORO-16BETA-METHYLPREDNISOLONE
9alpha -Fluoro-16alpha -methylprednisolone
9alpha-Fluoro-16alpha-methylprednisolone
9alpha-Fluoro-16alpha-methyl-prednisolone
9-alpha-Fluoro-16-alpha-methylprednisolone
9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11alpha -methylpregna-1,4-diene-3,20-dione
9-Fluoro-16-methylprednisolone
9α-Fluoro-16α-methylprednisolone
9Α-fluoro-16α-methylprednisolone
AC-11056
AC1L1L1H
AC1Q29DM
Adexone
Aeroseb-D
Aeroseb-dex
Aeroseb-Dex
AI3-50934
Ak dex OPH otic soln 0.1%
Alcon brand OF dexamethasone
Alcon Brand of Dexamethasone
alpha -Fluoro-16-alpha -methylcortisol
Anaflogistico
Aphtasolon
Aphthasolone
Apo-dexamethasone
Auxiron
Azimycin (veterinary)
Azium
Azium (veterinary)
Azium (Veterinary)
BIDD:ER0494
BIDD:PXR0060
Bisu Ds
Bisu DS
BRD-K38775274-001-02-3
BRD-K38775274-001-06-4
BSPBio_000995
C15643
C22H29FO5
Calonat
CCRIS 7067
CHEBI:41879
CHEMBL384467
CID5743
Corson
Corsone
Cortisumman
CPD001227192
CPD-10549
D00292
D003907
D1756_SIGMA
D4902_SIGMA
D6645_SIGMA
D8893_SIGMA
D9184_SIGMA
DB01234
Decacort
Decacortin
Decaderm
Decadron
Decadron (TN)
Decadron Tablets, Elixir
Decadron, Dexamethasone
Decadron-La
Decadron-LA
Decagel
Decaject
Decaject l.a.
Decaject L.A.
Decaject-l.a.
Decaject-L.A.
Decalix
Decameth
Decasone
Decaspray
Dectancyl
Dekacort
delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta1-9alpha-Fluoro-16alpha-methylcortisol
Delta1-9alpha-Fluoro-16alpha-methylcortisol
Deltafluorene
Dergramin
Deronil
Desadrene
Desametasone
Desametasone [Dcit]
Desametasone [DCIT]
Desamethasone
Desameton
Deseronil
DEX
Dexa
DEXA
Dexa mamallet
Dexa Mamallet
Dexacen-4
Dexacidin
Dexacort
Dexacortal
Dexa-cortidelt
Dexa-Cortidelt
Dexacortin
Dexa-cortisyl
Dexa-Cortisyl
Dexadeltone
Dexafarma
Dexair
Dexalona
Dexaltin
Dexa-Mamallet
Dexametasona
Dexametasona [INN-Spanish]
Dexametasone
Dexameth
Dexamethansone
dexamethasone
Dexamethasone
Dexaméthasone
Dexamethasone (JP15/USP/INN)
Dexamethasone [INN:BAN:JAN]
Dexamethasone acetate
|
Dexamethasone Acetate
Dexamethasone alcohol
Dexamethasone Alcohol
Dexamethasone base
Dexamethasone Base
Dexamethasone intensol
Dexamethasone Intensol
Dexamethasone sodium phosphate
Dexamethasone Sodium Phosphate
Dexamethasone-omega
Dexamethasonum
Dexamethasonum [INN-Latin]
Dexamethazone
Dexamonozon
Dexapolcort
Dexapos
Dexaprol
Dexa-scheroson
Dexa-Scheroson
Dexa-sine
Dexa-Sine
Dexason
Dexasone
Dexasone 0.5MG
Dexasone 0.75MG
Dexasone 4MG
Dexasporin
Dex-ide
Dex-Ide
Dexinolon
Dexinoral
Dexone
Dexone 0.5
DEXONE 0.5
Dexone 0.75
DEXONE 0.75
Dexone 1.5
DEXONE 1.5
Dexone 4
DEXONE 4
Dexonium
Dexpak
Dextelan
Dezone
Dinormon
DXM
Dxms
DXMS
ECR brand OF dexamethasone
ECR Brand of Dexamethasone
EINECS 200-003-9
Fluormethylprednisolone
Fluormone
Fluorocort
Fortecortin
Foy brand OF dexamethasone
Foy Brand of Dexamethasone
FT-0080377
Gammacorten
Hexadecadrol
Hexadrol
Hexadrol elixir
Hexadrol Elixir
Hexadrol Tablets
Hl-dex
Hl-Dex
HL-Dex
HMS1792A17
HMS1990A17
HMS2089N13
HSDB 3053
I06-1196
ICN brand OF dexamethasone
ICN Brand of Dexamethasone
IontoDex
Isopto-dex
Isopto-Dex
Lokalison F
Loverine
LS-7300
Luxazone
Maxidex
Maxidex ont 0.1%
Maxidex sus 0.1%
Maxitrol
Mediamethasone
Merck brand OF dexamethasone
Merck Brand of Dexamethasone
Merz brand 1 OF dexamethasone
Merz Brand 1 of Dexamethasone
Merz brand 2 OF dexamethasone
Merz Brand 2 of Dexamethasone
Methylfluorprednisolone
Mexidex
Millicorten
MK 125
MLS001055412
MLS001332507
MLS001332508
MolMap_000018
MolPort-003-846-433
Mymethasone
Naquasone (veterinary)
NCGC00091019-01
NCGC00091019-02
NCGC00091019-03
NCGC00091019-04
NCGC00091019-05
nchembio809-comp2
NCI60_003067
Neomycin and polymyxin b sulfates and dexamethasone
Neomycin and polymyxin b sulphates and dexamethasone
NSC 34521
NSC34521
Ocu-trol
Ocu-Trol
Oradexon
OTO-104
Pet derm III
Pet Derm Iii
Pet Derm III
Pet-Derm Iii
PHL-Dexamethasone
PMS Dexamethasone elixir 0.5mg/5ML
PMS-Dexamethasone
Policort
Posurdex
Prednisolon F
Prednisolone F
Prodex
S1322_Selleck
SAM002548948
Sandoz dexamethasone
SGCUT00126
Sk-Dexamethasone
SK-Dexamethasone
SMP1_000092
SMR000857119
SMR001227192
Spectrum5_002019
Spoloven
ST50307091
Sunia sol D
Sunia Sol D
Superprednol
TL8003317
to_000038
Tobradex
Tobramycin and dexamethasone
Tresaderm (veterinary)
Turbinaire
UNII-7S5I7G3JQL
Visumetazone
WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ G1
ZINC03875332
|
|
7 |
|
Tobramycin |
Approved, Investigational |
Phase 4 |
|
32986-56-4 |
5496 36294 |
Synonyms:
11098-01-4
11111-45-8
1-Epitobramycin
32986-56-4
34337-51-4
37321-13-4
3'-Deoxykanamycin b
3'-Deoxykanamycin B
49842-07-1 (Sulfate)
54330-95-9
70322-33-7
79645-27-5
A 12253A
AB00513858
AC1L1KGY
AC1L1VI0
AC1O7GFJ
AC1Q2AOW
AKOS000715235
Aktob
BAS 00463364
Bethkis
BIDD:GT0503
BPBio1_000647
BRN 1357507
Brulamycin
BSPBio_000587
BSPBio_002036
C00397
C18H37N5O9
CAS-32986-56-4
CHEBI:28864
CHEBI:533587
CHEMBL1747
CID11340303
CID36294
CID5496
CID6604388
CID9804613
CID9934285
CPD000058793
D00063
DB00684
Deoxykanamycin B
Distobram
EINECS 251-322-5
Gernebcin
Gotabiotic
HMS1569N09
HMS2090B16
HMS2092M17
HSDB 3259
KBio2_001552
KBio2_004120
KBio2_006688
KBio3_001536
KBioGR_001104
KBioSS_001552
Lilly 47663
LS-146940
LS-187329
MLS000069544
MolPort-001-934-131
MolPort-003-665-548
MolPort-003-939-629
NCGC00016814-01
NCGC00178852-01
NCGC00178852-02
Nebcin
Nebcin (Sulfate)
Nebicin
Nebramycin
NEBRAMYCIN
Nebramycin 6
|
Nebramycin factir 6
Nebramycin Factir 6
Nebramycin factor 6
Nebramycin Factor 6
Nebramycin Vi
Nebramycin VI
NF 6
NSC 180514
NSC180514
O-3-Amino-3-deoxy-a-D-glucopyranosyl-(1-4)-O-(2,6-diamino-2,3,6-trideoxy-a-D-ribohexopyranosyl-(1-4))-2-deoxy-D-streptamine
O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribohexopyranosyl-(1-4))-2-deoxy-D-streptamine
O-3-Amino-3-deoxy-α-D-glucopyranosyl-(1-4)-O-(2,6-diamino-2,3,6-trideoxy-α-D-ribohexopyranosyl-(1-4))-2-deoxy-D-streptamine
Obracin
Obramycin
Prestwick_850
Prestwick0_000544
Prestwick1_000544
Prestwick2_000544
Prestwick3_000544
S2514_Selleck
SAM001246911
SMR000058793
SPBio_000295
SPBio_002508
Spectrum_001072
SPECTRUM1500579
Spectrum2_000078
Spectrum3_000588
Spectrum4_000752
Spectrum5_001038
SPRC-AB01
STK182610
Sulfate, tobramycin
Sybryx
T4014_SIGMA
Tenebrimycin
Tenemycin
TOA-(1-6)2TB-(4-1)TOC
TOA-(1-6)TOB-(4-1)TOC
TOB
Tobacin
Tobi
Tobracin
Tobracin (TN)
Tobradex
Tobradistin
Tobralex
Tobramaxin
Tobramicin
Tobramicina
Tobramicina [INN-Spanish]
Tobramitsetin
Tobramycetin
tobramycin
Tobramycin
Tobramycin (JP15/USP)
Tobramycin [USAN:BAN:INN:JAN]
Tobramycin for Inhalation
tobramycin solution for inhalation
Tobramycin solution for inhalation
Tobramycin sulfate
Tobramycin Sulfate
TOBRAMYCIN SULFATE
Tobramycin, Free Base
Tobramycine
Tobramycine [INN-French]
Tobramycinum
Tobramycinum [INN-Latin]
Tobrased
Tobrasone
Tobrex
Tobrex (TN)
TOY
UNII-VZ8RRZ51VK
|
|
8 |
|
Bromfenac |
Approved |
Phase 4 |
|
91714-94-2 |
60726 |
Synonyms:
[2-Amino-3-(4-bromo-benzoyl)-phenyl]-acetate
[2-amino-3-(4-bromobenzoyl)phenyl]acetic acid
[2-Amino-3-(4-bromo-benzoyl)-phenyl]-acetic acid
{2-amino-3-[(4-bromophenyl)carbonyl]phenyl}acetic acid
2-[2-amino-3-(4-bromobenzoyl)phenyl]acetic acid
2-Amino-3-(4-bromobenzoyl)benzeneacetate
2-amino-3-(4-bromobenzoyl)benzeneacetic acid
2-Amino-3-(4-bromobenzoyl)benzeneacetic acid
91714-94-2
AC1L1TSW
AC1Q5DQ7
AHR-10282
Ambap120638-55-3
Bromfenac
Bromfenac (INN)
Bromfenac [INN]
Bromfenac sodium
BROMFENAC SODIUM
Bromfenaco
|
Bromfenaco [Spanish]
Bromfenacum
Bromfenacum [Latin]
C15H12BrNO3
CHEBI:240107
CHEMBL1077
CID60726
D07541
DB00963
Duract
ISV-303
LS-178156
MolPort-000-883-091
sodium 2-amino-3-(4-bromobenzoyl) phenylacetate sesquihydrate
Sodium bromfenac
UNII-864P0921DW
Wyeth brand OF sodium bromfenac
Xibrom
|
|
9 |
|
Travoprost |
Approved |
Phase 4 |
|
157283-68-6 |
5282226 |
Synonyms:
(((1R)-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester
(+)-Fluprostenol isopropyl ester
(1R-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-7-(3,5-Dihydroxy-2-(3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester
(Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3R)-3-hydroxy-4-((alpha,alpha,alpha-trifluoro-m-isopropyl-tolyl)oxy)-1-butenyl)cyclopentyl)-5-heptenoate
157283-68-6
5-Heptenoic acid,7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3R)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-,1-methylethyl ester,(5Z)
AC1NQZOS
AC-6103
AL6221
AL-6221
C26H35F3O6
CHEBI:746859
CHEMBL1200799
CID5282226
D01964
DB00287
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(a,a,a-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(a,a,a-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoic acid
isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(alpha,alpha,alpha-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(alpha,alpha,alpha-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate
|
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(alpha,alpha,alpha-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoic acid
isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(α,α,α-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(α,α,α-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(α,α,α-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoic acid
LS-173521
propan-2-yl (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-en-1-yl}cyclopentyl]hept-5-enoate
propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoate
S1554_Selleck
Travatan
Travatan (TN)
Travatan Alcon
Travatan Z
Travatan, Travoprost
Travatanz
Travoprost
Travoprost (JAN/USAN/INN)
Travoprost [USAN]
Travoprostum
Z, Travatan
ZINC04474682
|
|
10 |
|
Heparin |
Approved, Investigational |
Phase 4 |
|
9005-49-6 |
772 9812414 |
Synonyms:
101921-26-0
102785-31-9
102-94-3
104521-37-1
11078-24-3
11129-39-8
12656-11-0
37324-73-5
9041-08-1
9045-22-1
9075-96-1
913079-23-9
91449-79-5
AC1L1ROY
ALFA 87-120
ALFA 87-163
ALFA 87-198
ALFA 87-81
ALFA 88-247
Allocinnamic acid
alpha-Heparin
Alpha-Heparin
Ardeparin
Ardeparin sodium
Ariven
Arteven
Bemiparin
Bemiparin sodium
Calcilean
Calciparine
Certoparin
CID8784
cis-.beta.-Carboxystyrene
cis-Cinnamic acid
Clexane
Clivarin
Clivarine
CY 216
Cy 222
Dalteparin
Dalteparin sodium
Depo-Heparin
EINECS 232-681-7
Enoxaparin
Enoxaparin sodium
Eparina
Eparina [DCIT]
Fluxum
FR 860
Fragmin A
Fragmin B
Fragmin IV
Fraxiparin
H 2149
Hed-heparin
Hed-Heparin
Hep Flush Kit in plastic container
Hepalean
heparin
Heparin Cy 216
Heparin CY 216
Heparin Leo
Heparin Lock Flush
Heparin Lock Flush in plastic container
Heparin Lock Flush preservative free
Heparin Lock Flush preservative free in plastic container
Heparin natrium
Heparin sodium
Heparin sodium 1,000 units and sodium chloride 0.9% in plastic container
Heparin sodium 1,000 units in dextrose 5% in plastic container
Heparin sodium 1,000 units in sodium chloride 0.9% in plastic container
Heparin sodium 10,000 units in dextrose 5%
Heparin sodium 10,000 units in dextrose 5% in plastic container
Heparin sodium 10,000 units in sodium chloride 0.45%
Heparin sodium 10,000 units in sodium chloride 0.9%
Heparin sodium 12,500 units in dextrose 5%
Heparin sodium 12,500 units in dextrose 5% in plastic container
Heparin sodium 12,500 units in sodium chloride 0.45% in plastic container
Heparin sodium 12,500 units in sodium chloride 0.9%
Heparin sodium 2,000 units and sodium chloride 0.9% in plastic container
Heparin sodium 2,000 units in dextrose 5% in plastic container
Heparin sodium 2,000 units in sodium chloride 0.9% in plastic container
Heparin sodium 20,000 units and dextrose 5% in plastic container
Heparin sodium 20,000 units in dextrose 5% in plastic container
Heparin sodium 25,000 units and dextrose 5% in plastic container
Heparin sodium 25,000 units in dextrose 5%
|
Heparin sodium 25,000 units in dextrose 5% in plastic container
Heparin sodium 25,000 units in sodium chloride 0.45% in plastic container
Heparin sodium 25,000 units in sodium chloride 0.9%
Heparin sodium 25,000 units in sodium chloride 0.9% in plastic container
Heparin sodium 5,000 units and sodium chloride 0.9% in plastic container
Heparin sodium 5,000 units in dextrose 5% in plastic container
Heparin sodium 5,000 units in sodium chloride 0.45%
Heparin sodium 5,000 units in sodium chloride 0.9%
Heparin sodium 5,000 units in sodium chloride 0.9% in plastic container
Heparin sodium in plastic container
Heparin sodium preservative Free
Heparin sodium salt
Heparin sulfate
Heparin sulphate
Heparin, sodium salt
Heparina
Heparina [INN-Spanish]
Heparinate
Heparine
Heparine [INN-French]
Heparinic acid
Heparinsodiumsalt
Heparinum
Heparinum [INN-Latin]
Heparinum natricum
Hepathrom
Hepflush-10
Hep-Lock
Hep-Lock U/P
HSDB 3094
Innohep
Inno-Hep
Isocinnamic acid
Kabi 2165
KB 101
Leparan
LHN 1
Lioton 1000
Lipo-hepin
Lipo-Hepin
Liquaemin
Liquaemin Lock Flush
Liquaemin Sodium
Liquaemin sodium preservative free
Liquemin
Logiparin
Low molecular weight heparin sodium
Minolteparin sodium
MolPort-003-760-257
Multiparin
Nadroparin
Nadroparine
Novoheparin
NSC174025
Octaparin
OP 386
OP 622
Pabyrin
Panheprin
Parnaparin
Parnaparin sodium
Parvoparin
Pularin
Reviparin
Reviparin sodium
Ro 11
Sandoparin
Sodium acid heparin
Sodium heparin
Sodium heparinate
Subeparin
Sublingula
Thromboliquine
Tinzaparin
Tinzaparin sodium
Triofiban
Unfractionated heparin
UNII-12M44VTJ7B
UNII-3S182ET3UA
UNII-E47C0NF7LV
UNII-T2410KM04A
UNII-ZZ45AB24CA
Vetren
Vitrum AB
WY 90493RD
|
|
11 |
|
Dorzolamide |
Approved |
Phase 4 |
|
120279-96-1 |
3154 5284549 |
Synonyms:
(4S,6S)-4-(ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide
(4S,6S)-4-(ethylamino)-6-methyl-7,7-dioxo-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide
(4S,6S)-4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonate amide
(4S,6S)-4-ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonic acid amide
(4S,6S)-4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonic acid amide
(4S,6S)-4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulphonate amide
(4S,6S)-4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulphonic acid amide
(4S,trans)-4-(ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide
(4S,trans)-4-(Ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide
(4S,trans)-4-(Ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulphonamide 7,7-dioxide
(4S-trans)-4-(ETHYLAMINO)-5,6-dihydro-6-methyl-4H-thieno(2,3-b)thiopyran-2-sulfonamide-7,7-dioxide
(4S-TRANS)-4-(ETHYLAMINO)-5,6-DIHYDRO-6-METHYL-4H-THIENO(2,3-B)THIOPYRAN-2-SULFONAMIDE-7,7-DIOXIDE
(4S-trans)-4-(ETHYLAMINO)-5,6-dihydro-6-methyl-4H-thieno(2,3-b)thiopyran-2-sulphonamide-7,7-dioxide
120279-96-1
1cil
4-Ethylamino-5,6-dihydro-6-methyl-7,7-dioxide-4H-thieno(2,3-b)thiopyran-2-sulfonamide
4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonate amide
4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonic acid amide
4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulphonate amide
4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulphonic acid amide
4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda6-thieno[2,3-b]thiopyran-2-sulfonate amide
4-ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda6-thieno[2,3-b]thiopyran-2-sulfonic acid amide
4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda6-thieno[2,3-b]thiopyran-2-sulfonic acid amide
4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda6-thieno[2,3-b]thiopyran-2-sulphonate amide
4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda6-thieno[2,3-b]thiopyran-2-sulphonic acid amide
4S,6S-dorzolamide
4S,6S-Dorzolamide
5,6-Dihydro-4-ethylamino-6-methyl-4H-thieno(2,3-b)thiopyran-2-sulfonamide-7,7-dioxide
AB00514687
AC1NR4NP
|
BIDD:GT0306
BPBio1_001377
BRD-K48617017-003-03-1
BSPBio_001252
C06969
CHEBI:4702
CHEMBL218490
CID5284549
D07871
DB04507
Dorzolamid
Dorzolamida
dorzolamide
Dorzolamide
Dorzolamide (DZA)
Dorzolamide (INN)
Dorzolamide chibret
Dorzolamide hydrochloride
Dorzolamide, (trans)-isomer
Dorzolamidum
HMS2089O06
MolPort-005-941-739
Prestwick0_001116
Prestwick1_001116
Prestwick2_001116
Prestwick3_001116
SPBio_003116
STK645522
Trusopt
Trusopt (TN)
|
|
12 |
|
Cloprostenol |
Vet_approved |
Phase 4 |
|
54276-21-0 |
|
13 |
|
Maleic acid |
Experimental |
Phase 4 |
|
110-16-7 |
444266 |
Synonyms:
(2Z)-2-Butenedioate
(2Z)-2-Butenedioic acid
(2Z)-But-2-enedioate
(2Z)-But-2-enedioic acid
(2Z)-Butene-2-dioate
(2Z)-Butene-2-dioic acid
(Z)-2-Butenedioate
(Z)-2-Butenedioic acid
(Z)-Butenedioate
(Z)-Butenedioic acid
2-Butenedioate
2-Butenedioic acid
cis-1,2-Ethylenedicarboxylate
cis-1,2-Ethylenedicarboxylic acid
cis-2-Butenedioate
cis-2-Butenedioic acid
cis-But-2-enedioate
cis-But-2-enedioic acid
cis-Butenedioate
cis-Butenedioic acid
H2Male
Hydrogen maleate
|
Kyselina maleinova
MAE
Maleate
Maleic acid, ammonium salt
Maleic acid, calcium salt
Maleic acid, dipotassium salt
Maleic acid, disodium salt
Maleic acid, iron salt
Maleic acid, monoammonium salt
Maleic acid, monocopper (2+) salt
Maleic acid, monosodium salt
Maleic acid, neodymium salt
Maleic acid, potassium salt
Maleic acid, sodium salt
Maleinic acid
Malenic acid
Malezid CM
Scotchbond multipurpose etchant
Sodium maleate
Toxilate
Toxilic acid
|
|
14 |
|
Ketorolac Tromethamine |
|
Phase 4 |
|
|
|
15 |
|
Anti-Inflammatory Agents |
|
Phase 4 |
|
|
|
16 |
|
Pharmaceutical Solutions |
|
Phase 4 |
|
|
|
17 |
|
Hormone Antagonists |
|
Phase 4 |
|
|
|
18 |
|
glucocorticoids |
|
Phase 4 |
|
|
|
19 |
|
Hormones |
|
Phase 4 |
|
|
|
20 |
|
Anti-Inflammatory Agents, Non-Steroidal |
|
Phase 4 |
|
|
|
21 |
|
Ophthalmic Solutions |
|
Phase 4 |
|
|
|
22 |
|
Analgesics, Non-Narcotic |
|
Phase 4 |
|
|
|
23 |
|
Antineoplastic Agents, Hormonal |
|
Phase 4 |
|
|
|
24 |
|
Analgesics |
|
Phase 4 |
|
|
|
25 |
|
Adrenergic Antagonists |
|
Phase 4 |
|
|
|
26 |
|
Adrenergic Agents |
|
Phase 4 |
|
|
|
27 |
|
Anti-Arrhythmia Agents |
|
Phase 4 |
|
|
|
28 |
|
Adrenergic beta-Antagonists |
|
Phase 4 |
|
|
|
29 |
|
Contraceptive Agents |
|
Phase 4 |
|
|
|
30 |
|
Antihypertensive Agents |
|
Phase 4 |
|
|
|
31 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
32 |
|
Carbonic Anhydrase Inhibitors |
|
Phase 4 |
|
|
|
33 |
|
Antibiotics, Antitubercular |
|
Phase 4 |
|
|
|
34 |
|
Gastrointestinal Agents |
|
Phase 4 |
|
|
|
35 |
|
Anti-Bacterial Agents |
|
Phase 4 |
|
|
|
36 |
|
Anti-Infective Agents |
|
Phase 4 |
|
|
|
37 |
|
Antiemetics |
|
Phase 4 |
|
|
|
38 |
|
calcium heparin |
|
Phase 4 |
|
|
|
39 |
|
Triamcinolone |
Approved, Vet_approved |
Phase 2, Phase 3 |
|
124-94-7 |
31307 |
Synonyms:
(8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
11.Beta.,16.alpha.,17.alpha., 21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione
11.beta.,16.alpha.,17.alpha.,21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione
11b,16a,17a,21-Tetrahydroxy-9a-fluoro-1,4-pregnadiene-3,20-dione
11beta,16alpha,17alpha,21-Tetrahydroxy-9alpha-fluoro-1,4-pregnadiene-3,20-dione
11-beta,16-alpha,17-alpha,21-Tetrahydroxy-9-alpha-fluoro-1,4-pregnadiene-3,20-dione
11β,16α,17α,21-tetrahydroxy-9α-fluoro-1,4-pregnadiene-3,20-dione
11Β,16α,17α,21-tetrahydroxy-9α-fluoro-1,4-pregnadiene-3,20-dione
124-94-7
4-08-00-03629 (Beilstein Handbook Reference)
83474-03-7
9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahy
9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione
9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9.Alpha.-Fluoro-11.beta.,16.alpha.,17.alpha., 21-tetrahydroxypregna-1,4-diene-3,20-d
9.alpha.-Fluoro-11.beta.,16.alpha.,17.alpha.,21-tetrahydroxypregna-1,4-diene-3,20-dione
9.alpha.-Fluoro-16.alpha.-hydroxyprednisolone
9a-Fluoro-11b,16a,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9a-Fluoro-11b,16a,17a,21-tetrahydroxypregna-1,4-diene-3,20-dione
9a-Fluoro-16a-hydroxyprednisolone
9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione
9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-alpha-Fluoro-11-beta,16-alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9alpha-Fluoro-11beta,16alpha,17alpha,21-tetrahydroxypregna-1,4-diene-3,20-dione
9alpha-Fluoro-16alpha-hydroxyprednisolone
9-alpha-Fluoro-16-alpha-hydroxyprednisolone
9-Fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-Fluoro-11b,16a,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-Fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9α-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9Α-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9α-fluoro-11β,16α,17α,21-tetrahydroxypregna-1,4-diene-3,20-dione
9Α-fluoro-11β,16α,17α,21-tetrahydroxypregna-1,4-diene-3,20-dione
9α-fluoro-16α-hydroxyprednisolone
9Α-fluoro-16α-hydroxyprednisolone
AC1L1LDH
AC1Q5HJC
AC-2072
Adcortyl
Aristocort
Aristocort A
Aristocort Tablets
Aristogel
Aristospan
Azmacort
Bio-0662
BPBio1_000154
BRD-K77554836-001-03-3
BRN 2341955
BSPBio_000140
C21H27FO6
Celeste
CHEMBL1451
CID31307
Cinolone
Cinolone-T
CL 19823
D00385
D014221
DB00620
Delphicort
droxypregna-1,4-diene-3,20-dione
EINECS 204-718-7
EU-0101179
Fluoxiprednisolone
Fluoxyprednisolone
Flutex
Fougera
HMS1568G22
HMS2090D12
HSDB 3194
ione
Kenacort
Kenacort (TN)
Kenacort-A
Kenacort-Ag
Kenacort-AG
Kenalog
|
Kenalog in Orabase
Kenalog-10
Kenalog-40
Kenalog-H
Ledercort
Lopac0_001179
LS-698
MLS000028542
MLS001066543
MLS002695935
MolPort-002-528-981
Mycolog
Nasacort
Nasacort Aq
Nasacort Hfa
NCGC00021580-03
NCGC00021580-04
NCGC00021580-05
NCGC00021580-06
NCGC00021580-07
nchembio.2007.53-comp7
NCI60_000750
NSC 13397
NSC13397
Omcilon
Omicilon
Oracort
Oralone
Orion
Polcortolon
Pregna-1,4-diene-3,20-dio
Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11beta,16alpha)
Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,16alpha,17,21-tetrahydroxy- (8CI)
Prestwick_438
Prestwick0_000120
Prestwick1_000120
Prestwick2_000120
Prestwick3_000120
Rodinolone
S1933_Selleck
Sk-Triamcinolone
SK-Triamcinolone
SMP1_000300
SMR000058333
SPBio_002079
T6376_SIGMA
Tiamcinolonum
Tiamcinolonum [INN-Latin]
Triacet
Triacort
Triamcet
Triamcinalone
Triamcinlon
Triamcinolon
Triamcinolona
Triamcinolona [INN-Spanish]
triamcinolone
Triamcinolone
Triamcinolone (JP15/USP/INN)
TRIAMCINOLONE (SEE ALSO TRIAMCINOLONE ACETONIDE (76-25-5) AND TRIAMCINOLONE DIACETATE (67-78-7))
Triamcinolone [USAN:INN:BAN:JAN]
Triamcinolone acetonide
Triamcinolone diacetate
Triamcinolone hexacetonide
Triamcinolonum
Triamcinolonum [INN]
Triam-Tablinen
Triatex
Tricortale
Triderm
Trilone
Tri-Nasal
Tristoject
Trymex
UNII-1ZK20VI6TY
Vetalog
Volon
Volon A
WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ GQ
ZINC03882036
|
|
40 |
|
Apraclonidine |
Approved |
Phase 3 |
|
66711-21-5 |
2216 |
Synonyms:
2-(4-amino-2,6-dichloro)phenyliminoimidazolidine
2-(4-Amino-2,6-dichloro)phenyliminoimidazolidine
2-(4-Amino-2,6-dichloroanilino)-2-imidazoline hydrochloride
2,6-dichloro-1-N-(4,5-dihydro-1H-imidazol-2-yl)benzene-1,4-diamine
2,6-dichloro-N(1)-(4,5-dihydro-1H-imidazol-2-yl)benzene-1,4-diamine
4-Aminoclonidine
66711-21-5
A0779_SIGMA
AC-12697
AC1L1D6L
ALO 2145
Aplonidine
Apraclonidina
Apraclonidina [INN-Spanish]
apraclonidine
Apraclonidine
Apraclonidine (INN)
Apraclonidine [INN:BAN]
Apraclonidine hydrochloride
Apraclonidinum
Apraclonidinum [INN-Latin]
C07668
C9H10Cl2N4
CHEBI:127495
CHEBI:2788
CHEMBL647
|
CID2216
D07461
DB00964
Iopidine
Iopidine (TN)
Iopidine Eye
Iopimax
L000686
L013394
Lopac0_000033
Lopac-A-0779
LS-176536
MolPort-003-940-020
MolPort-005-933-986
NCGC00015033-01
NCGC00015033-03
NCGC00162050-01
p-aminoclonidine
p-Aminoclonidine
para-aminoclonidine
Para-aminoclonidine
PDSP1_000790
PDSP2_000778
SMP1_000016
UNII-843CEN85DI
ZINC00020231
|
|
41 |
|
Lubricant Eye Drops |
|
Phase 3 |
|
|
|
42 |
|
Immunosuppressive Agents |
|
Phase 2, Phase 3 |
|
|
|
43 |
|
Triamcinolone hexacetonide |
|
Phase 2, Phase 3 |
|
|
|
44 |
|
triamcinolone acetonide |
|
Phase 2, Phase 3 |
|
|
|
45 |
|
Triamcinolone diacetate |
|
Phase 2, Phase 3 |
|
|
|
46 |
|
Proxymetacaine |
|
Phase 3 |
|
|
|
47 |
|
Brimonidine Tartrate |
|
Phase 3 |
|
70359-46-5 |
|
48 |
|
Pancrelipase |
Approved, Investigational |
Phase 2 |
|
53608-75-6 |
|
Synonyms:
lipase
Pancrealipase
Pancreatic extract pancrelipase
Pancreatic protease
|
Pancreatin
Pancreatinum
Pancrelipase (amylase
protease)
|
|
49 |
|
Gemcitabine |
Approved |
Phase 2 |
|
95058-81-4 |
60750 |
Synonyms:
103882-84-4
122111-03-9
2',2'-DFDC
2',2'-DiF-dC
2',2'-Difluoro-2'-deoxycytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-.beta.-D-2',2'-difluorocytidine
2'-Deoxy-2',2'-difluorocytidine
2'-Deoxy-2',2''-difluorocytidine-5'-O-monophosphate
2'-Deoxy-2'-difluorocytidine
4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
4-Amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl]-1H-pyrimidin-2-one
95058-81-4
AB1004842
AC1L1TUQ
C07650
CCRIS 8984
CHEBI:175901
CHEMBL888
CID60750
Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine
D02368
DB00441
DDFC
DFdC
DFDC
DFdCyd
Folfugem
Gamcitabine
Gemcel
Gemcin
Gemcitabin
Gemcitabina
|
Gemcitabina [INN-Spanish]
gemcitabine
Gemcitabine
Gemcitabine (USAN/INN)
Gemcitabine HCl
Gemcitabine hydrochloride
Gemcitabine stereoisomer
Gemcitabine, (alpha-D-threo-pentofuranosyl)-isomer
Gemcitabine, (beta-D-threo-pentafuranosyl)-isomer
Gemcitabine, (D-threo-pentafuranosyl)-isomer
Gemcitabinum
Gemcitabinum [INN-Latin]
GemLip
Gemtro
Gemzar
Gemzar (hydrochloride)
GEO
HMS2089P10
HSDB 7567
Inno-D07001
LS-59139
LY 188011
LY188011
LY-188011
NCGC00168784-01
NChemBio.2007.10-comp25
nchembio.573-comp7
nchembio.90-comp2
NSC 613327
NSC613327
TL8005979
UNII-B76N6SBZ8R
Zefei
ZINC18279854
|
|
50 |
|
Cisplatin |
Approved |
Phase 2 |
|
15663-27-1 |
84093 441203 2767 |
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
Carboquone
CDDP
CHEBI:35852
CID441203
Cis Pt II
cis-[PtCl2(NH3)2]
cis-DDP
Cis-DDP
Cis-Diaminedichloroplatinum
cis-diamminedichloridoplatinum(II)
cis-Diamminedichloroplatinum
Cis-Diamminedichloroplatinum
cis-diamminedichloroplatinum(II)
cis-Dichlorodiammineplatinum(II)
Cismaplat
Cisplatin
Cisplatine
cisplatino
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
CPD0-1392
|
CPDC
CPDD
DB00515
DDP
DDPT
Diamminedichloroplatinum
EU-0100918
Lederplatin
nchembio773-comp1
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
trans-DDP
Trans-DDP
Trans-Diaminedichloroplatinum
trans-diamminedichloridoplatinum(II)
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
|
|
Interventional clinical trials:
(show top 50)
(show all 66)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A Prospective, Randomized Evaluation of Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost Ophthalmic Solution 0.004% |
Unknown status |
NCT01444040 |
Phase 4 |
Travoprost |
2 |
A Randomised Controlled Trial to Compare the Clinical Effectiveness of Selective Laser Trabeculoplasty (SLT) Versus Topical Therapy in the Treatment of Pseudoexfoliative Glaucoma |
Unknown status |
NCT01704989 |
Phase 4 |
Prostagladin |
3 |
24-Hour Intraocular Pressure Control Obtained With the Bimatoprost/Timolol Fixed Combination Compared With Latanoprost as First Choice Therapy in Subjects With Exfoliation Syndrome, or Exfoliative Glaucoma |
Completed |
NCT01448837 |
Phase 4 |
Bimatoprost/Timolol, 24-hour intraocular pressure monitoring;Latanoprost, 24-hour intraocular pressure monitoring |
4 |
The Reggio Emilia Study on Bromfenac for Patients With PseudoEXfoliation Syndrome Undergoing Cataract Surgery: the REPEX Study |
Completed |
NCT02137161 |
Phase 4 |
Dexamethasone+Tobramycin eye drop;Bromfenac eye drop |
5 |
Efficacy Of The Bimatoprost/Timolol Fixed Combination In Patients Treated With Bimatoprost for Primary Open Angle Glaucoma, Exfoliation Glaucoma or Ocular Hypertension. |
Completed |
NCT00941096 |
Phase 4 |
Bimatoprost and Bimatoprost/Timolol fixed combination. |
6 |
A Prospective, Randomized Evaluation of Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent) or Travoprost Ophthalmic Solution 0.004% |
Completed |
NCT01443988 |
Phase 4 |
Travoprost |
7 |
A Randomized Post-Marketing Efficacy And Safety Study Of Xalatan Compared With "Usual Care" Over 36 Months In Patients With Primary Open-Angle Glaucoma, Exfoliative Glaucoma Or Ocular Hypertension |
Completed |
NCT00140062 |
Phase 4 |
latanoprost 0.005% (Xalatan) |
8 |
24-hour IOP Control With the Travoprost/Timolol Fixed Combination Compared With the Latanoprost/Timolol Fixed Combination, When Both Are Dosed in the Evening in Patients With Exfoliative Glaucoma |
Completed |
NCT00757835 |
Phase 4 |
treatment with latanoprost/timolol fixed combination;latanoprost/timolol fixed combination drops |
9 |
A 3-month, 4-centre, Crossover, Double-masked Study Investigating the 24-hour Intraocular Pressure Control With the Bimatoprost/Timolol Fixed Combination Dosed Morning, or Evening in Subjects With Exfoliative Glaucoma |
Completed |
NCT00486486 |
Phase 4 |
Drug: bimatoprost/timolol fixed combination AM;Bimatoprost/timolol fixed combination dosed PM |
10 |
Aqueous Flare of a Hydrophobic Acrylic Single-piece Open-loop IOL With Modified Material Surface Properties |
Completed |
NCT01767012 |
Phase 4 |
|
11 |
Assessing Cosopt Switch Patients |
Completed |
NCT00273442 |
Phase 4 |
timolol maleate;dorzolamide/timolol maleate fixed combination |
12 |
The Effect of Intracameral Triesence (Triamcinolone Acetonide Injectable Suspension) on Ocular Inflammation After Trabeculectomy, Tube Shunt Implantation or Combined Trabeculectomy With Cataract Surgery |
Completed |
NCT00853905 |
Phase 2, Phase 3 |
Triesence;balanced salt solution BSS |
13 |
Randomized Multicentre Prospective Study of Selective Laser Trabeculoplasty (SLT) vs. Argon Trabeculoplasty (ALT) in Patients With Pseudoexfoliation Glaucoma and Ocular Hypertension |
Completed |
NCT01126203 |
Phase 3 |
|
14 |
24-Hour Intraocular Pressure (IOP) Control With Travoprost/Timolol Fixed Combination |
Completed |
NCT00331240 |
Phase 3 |
travoprost/timolol fixed combination;placebo (artificial tears) |
15 |
A Study to Assess the Safety, Efficacy and Tolerability of Rituximab (Mabthera) in Combination With Plasma Exchange (PEX) in Patients With Acute Thrombotic Thrombocytopenic Purpura (TTP) |
Unknown status |
NCT00937131 |
Phase 2 |
Rituximab |
16 |
A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma |
Completed |
NCT01936389 |
Phase 2 |
AR-12286 |
17 |
PEXG (Cisplatin, Epirubicin, Capecitabine, Gemcitabine) Versus PDXG (Cisplatin, Docetaxel, Capecitabine, Gemcitabine) in Locally Advanced or Metastatic Pancreatic Adenocarcinoma: A Randomized Phase II Trial |
Completed |
NCT00966706 |
Phase 2 |
capecitabine;cisplatin;docetaxel;epirubicin hydrochloride;gemcitabine hydrochloride |
18 |
Open-Label, Feasibility Study of Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids in Patients With Acute Idiopathic Pulmonary Fibrosis Exacerbations |
Completed |
NCT01266317 |
Phase 1, Phase 2 |
Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids |
19 |
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-blind Study in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) to Evaluate the Pharmacokinetics,Safety and Efficacy of rADAMTS-13 (SHP655) Administered in Addition to Standard Of Care (SoC) Treatment |
Recruiting |
NCT03922308 |
Phase 2 |
SHP655 |
20 |
A Multicenter, Open-Label, Phase II Study of Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids in Patients With Acute Idiopathic Pulmonary Fibrosis Exacerbations |
Withdrawn |
NCT01524068 |
Phase 2 |
Standard Steroid Treatment;The Standard Steroid Treatment, Plasma Exchange and rituximab |
21 |
Kinetic Study of Human Pharmacokinetics in Normal Renal Function, and Renal Insufficiency Subject of Polyethylene Glycol Loxenatide (PEX168)(Open, Non-randomized, Parallel-group) |
Unknown status |
NCT02467790 |
Phase 1 |
PEX168 |
22 |
Prospective Study to Examine the Efficacy of a Capsular Tension Ring (CTR) in Preventing Anterior Capsule Shrinkage After Cataract Surgery in Exfoliation Syndrome (XFS) With no Zonular Weakness |
Unknown status |
NCT01455168 |
|
|
23 |
The Corneal Endothelial Cell Count in Eyes With Pseudoexfoliation Syndrome |
Unknown status |
NCT03265457 |
|
|
24 |
The International Collaborative Exfoliation Syndrome Treatment Study |
Unknown status |
NCT00804115 |
|
Latanoprost with Pilocarpine vs Timolol or Cosopt |
25 |
Evaluation of LOXL1 Polymorphism in Pseudoexfoliation Syndrome in the Korean Population |
Unknown status |
NCT01515735 |
|
|
26 |
Comparison of the Capsular Stability With Two Different IOL Models in Patients With Pseudoexfoliation Syndrome: an Exploratory Study |
Unknown status |
NCT02155478 |
|
|
27 |
Prediction of Pseudophakodonesis After Uneventful Cataract Surgery |
Unknown status |
NCT03751462 |
|
|
28 |
Measurement of Ocular Tensional Fluctuation by Triggerfish Lens Before and After Cataract Surgery in Patients With Exfoliative Glaucoma |
Unknown status |
NCT02658071 |
|
|
29 |
Glaucoma Including Pseudoexfoliation Syndrome (SFB 539) |
Unknown status |
NCT00947869 |
|
|
30 |
Glaucoma Including Pseudoexfoliation Syndrome (SFB 539) |
Unknown status |
NCT00494923 |
|
|
31 |
Following Patients After Selective and Pascal Laser Trabeculoplasty for Treatment of Chronic Open-Angle Glaucoma |
Unknown status |
NCT02679482 |
|
|
32 |
IOP Monitoring After Trabeculectomy Using iCare Home |
Unknown status |
NCT03445806 |
|
|
33 |
Monitoring of the Intraocular Pressure After Selective Laser Trabeculoplasty Using iCare Home |
Unknown status |
NCT03310788 |
|
|
34 |
Anti-inflammatory Therapy Following Selective Laser Trabeculoplasty (SLT): A Randomized, Masked, Placebo Controlled Study |
Completed |
NCT00485108 |
|
prednisolone 1%;ketorolac 0.5%;Artificial Tears (Methyl cellulose drops) |
35 |
Pseudoexfoliation Syndrome in Myopes Defined With Optical Low Coherence Reflectometry |
Completed |
NCT01637740 |
|
|
36 |
Clinical Factors Associated With Floppy Iris Signs: a Prospective Study From Two Centers |
Completed |
NCT00472888 |
|
|
37 |
Central Corneal Thickness in Patients With Exfoliation Syndrome, Exfoliative Glaucoma, Exfoliative Glaucoma, Primary Open-angle Glaucoma and Ocular Hypertension |
Completed |
NCT01023997 |
|
|
38 |
Plasma Levels of Matrix Metalloproteinases and Degree of DNA Fragmentation in Patients With Pseudoexfoliation Syndrome and Open-Angle Glaucoma (PEXG) |
Completed |
NCT00327613 |
|
|
39 |
Evaluation of Scanning Laser Polarimetry Findings in Individuals With Exfoliation Syndrome Compared With Normal Controls |
Completed |
NCT01022281 |
|
|
40 |
Study of the Efficacy of a Single Session Micropulse Laser Trabeculoplasty as an Adjunctive Measure in Decreasing Intraocular Pressure in Patients Suffering From Pseudoexfoliation Glaucoma |
Completed |
NCT03483402 |
|
|
41 |
Optical Low Coherence Reflectometry Enables Preoperative Detection of Zonular Weakness in Pseudoexfoliation Syndrome |
Completed |
NCT01298895 |
|
|
42 |
Assessment of Long-term Intraocular Lens (IOL) Decentration and Tilt in Eyes With Pseudoexfoliation Syndrome (PES) Following Cataract Surgery |
Completed |
NCT03453827 |
|
|
43 |
Changes in Ocular Rigidity After Trabeculectomy in Patients With POAG or PEX |
Completed |
NCT02544646 |
|
|
44 |
Evaluation of Choroidal Thickness Using Spectral Optical Coherence Tomography in Pseudoexfoliation Glaucoma and Primary Open Angle Glaucoma |
Completed |
NCT03373942 |
|
|
45 |
The Diurnal and Nocturnal Effect of Simbrinza and Timolol on Intraocular Pressure and Ocular Perfusion Pressure |
Completed |
NCT02165631 |
|
|
46 |
A Comparison of the Additivity of Brinzolamide Ophthalmic Suspension, 1% (Azopt) and Brimonidine Tartrate Ophthalmic Solution, 0.15% (Alphagan P) to Travoprost Ophthalmic Solution, 0.004% (Travatan) in Patients With Elevated IOP on Travoprost. A Three Month Double-Masked, Multi-Center Trial in the United States |
Completed |
NCT00121147 |
|
Travatan;Azopt;Alphagan P |
47 |
A 3-month, Observational Study Investigating With Electronic Monitoring the Level of Adherence and Treatment Satisfaction With Latanoprost/Timolol Fixed Combination Versus Unfixed Therapy in Open-angle Glaucoma |
Completed |
NCT01281020 |
|
|
48 |
A Prospective Cohort Study of Contingency Management Using A Smartphone Application in Patients With Substance Use Disorder |
Completed |
NCT04162132 |
|
|
49 |
A Prospective Randomised Trial Comparing Selective Laser Trabeculoplasty (SLT) and iStent Trabecular Micro-bypass Stent Implantation Combined With Cataract Surgery in Exfoliation Glaucoma |
Recruiting |
NCT04635020 |
|
|
50 |
Cataract Surgery in Patients With Pseudoexfoliation and Pseudoexfoliation Glaucoma |
Recruiting |
NCT04590651 |
|
|
|